1778 FDG PET/CT AS IMAGING BIOMARKER FOR ADVANCED RENAL CELL CARCINOMA

Abstract

You have accessJournal of UrologyKidney Cancer: Advanced1 Apr 20111778 FDG PET/CT AS IMAGING BIOMARKER FOR ADVANCED RENAL CELL CARCINOMA Noboru Nakaigawa, Masahiro Yao, Kazuhide Makiyama, Ryogo Minamimoto, Tomio Inoue, and Yoshinobu Kubota Noboru NakaigawaNoboru Nakaigawa Yokohama, Japan More articles by this author , Masahiro YaoMasahiro Yao Yokohama, Japan More articles by this author , Kazuhide MakiyamaKazuhide Makiyama Yokohama, Japan More articles by this author , Ryogo MinamimotoRyogo Minamimoto Yokohama, Japan More articles by this author , Tomio InoueTomio Inoue Yokohama, Japan More articles by this author , and Yoshinobu KubotaYoshinobu Kubota Yokohama, Japan More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2011.02.2106AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES The antitumor effect of molecular targeting therapeutics for renal cell carcinoma (RCC) is not cytotoxic. It is thought that the therapeutics suppress the biological activity of cancer cells. Although the strategy based on the biological activity of cancer is necessary, the biomarkers evaluating biological activity of RCC was not established. 18-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (FDG-PET/CT) is a useful non-invasive tool to evaluate the metabolic status of tumors and the metabolic status can be evaluated quantitatively using the index called standardized uptake value (SUV). We investigated the usefulness of SUV evaluated by FDG PET/CT for the management of advanced RCC prospectively. METHODS Total 39 patients with advanced RCC were evaluated by FDG PET/CT before systematic therapies. And the 19 patients who were treated (sorafenib 11 cases, sunitinib 8 cases) more than 3 weeks were evaluated again 1 month after treatment started. The impact of maximum SUV (SUV max; highest SUV in an individual patient) and change ratio of SUVmax on the prognosis was analyzed prospectively. RESULTS The SUVmax before treatment of 39 patients ranged between 1.4 and 16.6. The patients with RCC showing high SUVmax demonstrated poor prognosis (P=0.005 hazard ratio 1.326, 95% CI 1.089–1.614). The mean survival time of 7 patients with RCC showing SUVmax less than 7.0 was 716±43 days, that of 13 patiens with RCC showing SUVmax between 7.0 and 12.0 was 550±91 days, and that of 9 patients RCC showing SUVmax higher or 12.0 was 154±56 days (P=0.001). Of 19 patients treated more than 3 weeks, progression free survival of 10 patients whose SUVmax decreased more or 20% after treatment were 458±271 days and that of 9 patients whose SUVmax decreased less than 20% was146±47 days (P=0.004). CONCLUSIONS The SUVmax calculated by FDG PET/CT is an interesting index to predict prognosis and evaluate the response of molecular targeting therapies. The SUVmax has potency as  gImaging Biomarker h evaluating the biological activity of advanced RCC and will provide helpful information for clinical decision-making. © 2011 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 185Issue 4SApril 2011Page: e714 Advertisement Copyright & Permissions© 2011 by American Urological Association Education and Research, Inc.MetricsAuthor Information Noboru Nakaigawa Yokohama, Japan More articles by this author Masahiro Yao Yokohama, Japan More articles by this author Kazuhide Makiyama Yokohama, Japan More articles by this author Ryogo Minamimoto Yokohama, Japan More articles by this author Tomio Inoue Yokohama, Japan More articles by this author Yoshinobu Kubota Yokohama, Japan More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...